Five commercial kits for the assay of lipoprotein(a) were investigated and two of these, the Immuno Enzyquick and Biopool TintElize, both enzyme-linked immunoassays, were studied in detail. Whilst there was a strong correlation between the results obtained using the two methods there was a significant difference between the absolute values. In view of its higher precision at low levels and robust performance, the Enzyquick kit (Immuno Ltd) was selected for use in this laboratory.
KratzinHArmstrongVWNiehausMStructural relationship of an apolipoprotein(a) phenotype to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol Chem Hoppes-Seyler1987; 368: 1533–44.
3.
McLeanJWTomlinsonJEKuangWJA DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature1987; 300: 132–7.
4.
ScanuAM. Lipoprotein(a) a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med1988; 112: 1045–7.
5.
BergK. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand1963; 59: 369–82.
6.
DahlenGFrickMHBergKFurther studies of Lp(a) lipoprotein/pre-β1 lipoprotein in patients with coronary heart disease. Clin Genet1975; 8: 183–9.
7.
HoulstonRQuineyJMountJLipoprotein (a) and coronary heart disease in familial hypercholesterolemia. Lancet1988; ii: 405.
8.
DahlenGHGuytonJRAttarMAssociation of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation1986; 74: 758–65.
9.
AlbersJJAdolphsonJLHazzardWR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res1977; 18: 331–8.
10.
AlbersJJHazzardWR. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids1974; 9: 15–26.
11.
KostnerGMAvogaroPCazzolatoGLipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis1981; 38: 51–61.
12.
ArmstrongVWCremerPEberleEThe association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis1986; 62: 249–57.
13.
RhoadsGGDahlenGBergKLp(a) lipoprotein as a risk factor for myocardial infarction. J Amer Med Assoc1986; 256: 2540–4.
14.
AlbersJJCabanaVGWarnickGRLp(a) lipoproteins: relationship to sinking pre-beta lipoprotein, hyperlipoproteinemia and apolipoprotein B. Metabolism1975; 9: 1047–54.
15.
GuytonJRDahlenGHPatschWRelationship of lipoprotein(a) to race, apolipoprotein B and clinical parameters. Arteriosclerosis1983; 3: 478a.
16.
VessbyBKostnerGLithelHDiverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis1982; 44: 61–71.
17.
SteinEKumblaLFeamJComparison of lovastatin and resin effects of plasma apolipo-proteins E and Lp(a), tocopherol, retinol and carotenoids. In: 8th International Symposium on Atherosclerosis. Italy: CIC Edizione Internazionale, 1988; 893 (abstract).
18.
KostnerGKleinGKremplerF.Can serum Lp(a) concentration be lowered by drugs and/or diet? In: CarlsonLAOlssonAG eds. Treatment of Hyperlipo-proteinaemics. New York: Raven Press, 1984; 151–6.
19.
CarlsonLAHamstenAAsplundlA. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med1989; 226: 271–6.
